Confronto
FOXO4-DRI vs. Ganirelix
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
2074706-72-8
123246-29-7
Peso molecolare
3735 g/mol
1570.3 g/mol
Emivita
0.5 h
nessun dato
Sequenza
D-Retro-Inverso-Variante eines FOXO4-Peptid-Fragments (LTLRKEPASEIAQSILEAYSQNGWANRRSGGKR — D-Aminosäuren in umgekehrter Sequenz)nessun dato
Meccanismo d'azione
FOXO4-DRI
FOXO4-DRI is the D-retro-inverso variant of a peptide fragment of the FOXO4 transcription factor. In senescent cells, FOXO4 is bound to p53, which suppresses p53-mediated apoptosis — the cells survive in a secreting 'zombie-like' state (senescence-associated secretory phenotype, SASP). The DRI peptide disrupts this FOXO4-p53 binding, freeing p53, and the senescent cell initiates apoptosis. Healthy cells are largely unaffected because p53 is not held back by FOXO4 in them. This selectivity was the central finding of the original 2017 publication.
Ganirelix
Ganirelix competitively and reversibly binds the pituitary GnRH receptor, rapidly suppressing LH (and, less so, FSH) release — without the initial hormone 'flare' of GnRH agonists.
Base di evidenze
Evidenza più alta
Modello animale
RCT sull'uomo
Studi
3
1
di cui sull'uomo
0
1
Effetti registrati
3
2
Contraddizioni aperte
1
0
Eventi avversi documentati
1
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between FOXO4-DRI and Ganirelix?
- FOXO4-DRI is classified as "Ricerca (altro)", while Ganirelix is classified as "Ricerca (altro)". FOXO4-DRI: Synthetic peptide with D-Retro-Inverso structure (all amino acids as D-form, sequence reversed), developed in 2017 as an experimental senolytic candidate. Goal: selective apoptosis of senescent cells via disruption of the FOXO4-p53 interaction. So far evaluated exclusively preclinically. Ganirelix: Ganirelix is a synthetic decapeptide and GnRH antagonist. In assisted reproduction (IVF) it prevents the premature LH surge during controlled ovarian stimulation. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, FOXO4-DRI or Ganirelix?
- The highest available evidence level is "Modello animale" for FOXO4-DRI and "RCT sull'uomo" for Ganirelix. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of FOXO4-DRI and Ganirelix in Germany and the United States?
- Germania: FOXO4-DRI — Solo ricerca, Ganirelix — Su prescrizione. Stati Uniti: FOXO4-DRI — Solo ricerca, Ganirelix — Su prescrizione. These are factual summaries with source and review date on the individual pages.